NKARTA INC (NKTX:NASDAQ)
$3.32 -0.17 (-4.8711%)
Analysed NKARTA INC (NKTX:NASDAQ) News Sources
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
17-04-2026
yahoo.com
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
15-04-2026
yahoo.com
Nkarta to Participate in Needham Virtual Healthcare Conference
09-04-2026
yahoo.com
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
25-03-2026
yahoo.com
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
10-03-2026
yahoo.com
Nkarta to Participate in March Investor Conferences
27-02-2026
yahoo.com
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
21-01-2026
fool.com
We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully
04-12-2025
yahoo.com
Nkarta to Participate in Evercore Healthcare Conference
02-12-2025
yahoo.com
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
10-11-2025
yahoo.com
What is the current price of NKARTA INC (NKTX:NASDAQ)?
The current price of NKARTA INC (NKTX:NASDAQ) is $3.32.
NKARTA INC (NKTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of NKARTA INC (NKTX:NASDAQ) since the previous trading day is $-0.17.
NKARTA INC (NKTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of NKARTA INC (NKTX:NASDAQ) since the previous trading day is -4.8711%.
What is the most recent average sentiment score for NKARTA INC (NKTX:NASDAQ)?
The most recent average sentiment score for NKARTA INC (NKTX:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for NKARTA INC (NKTX:NASDAQ)?
The most recent sentiment for NKARTA INC (NKTX:NASDAQ) is .
SEC-8K** Filing Available For NKARTA INC (NKTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.